PTPRC and neoplasm: Further, significantly more CD4-positive or CD8-positive CD3+CD45.1− cells expressed PD-1 in the combination treatment group when compared to the CART-alone group in the PDA7940b or B16-huCD19 tumor models, respectively (Supplementary Fig. 9b).